Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Active not recruiting 4

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 3Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 124daratumumab 73Lenalidomide 72Bortezomib 61pomalidomide 45Cyclophosphamide 41carfilzomib 40Calcium Dobesilate 36Specimen Handling 34Biopsy 30Magnetic Resonance Spectroscopy 27belantamab mafodotin 24isatuximab 20fludarabine 20dexamethasone acetate 18dexamethasone 21-phosphate 18auricularum 18Melphalan 18talquetamab 16iberdomide 16fludarabine phosphate 12selinexor 11elotuzumab 10X-Rays 10tocilizumab 9Nivolumab 8Sirolimus 7Crizotinib 7trametinib 6Whole-Body Irradiation 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Thalidomide × Plasma cell × 90 days × Clear all
NCT00602641 2026-05-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
306 enrolled 12 charts
Plasma cell

Multiple Myeloma

NCT00734877 2026-05-22

TT4B

University of Arkansas

Phase 3 Active not recruiting
382 enrolled
Plasma cell

Multiple Myeloma

NCT00869232 2026-05-22

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

University of Arkansas

Phase 2 Active not recruiting
90 enrolled
Plasma cell

Multiple Myeloma

NCT00871013 2026-05-11

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

University of Arkansas

Phase 2 Active not recruiting
160 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡